Sites Inria

Version française


S. A. (relu M-L.G.) - 31/10/2017

Launch of the Inria Neuromarkers Project Lab

On Tuesday 31 October 2017, Alexis Brice, Director General of the ICM, Antoine Petit, Chairman and CEO of Inria and François Sillion, Deputy CEO for Science, launched the Inria Neuromarkers Project Lab, the new IPL seeking to design new IT and statistical approaches for the prediction and study of the evolution of neurodegenerative diseases. 

A new large-scale collaborative project, the Inria Neuromarkers Project Lab brings together the multidisciplinary expertise of research teams from Inria (Aramis, Bonsai, Dyliss, Genscale, Xpop) and the ICM (Brain and Spine Institute) in the fields of: statistical learning, brain imaging, bioinformatics, knowledge modelling, genomics and neurodegenerative diseases.

A major public health issue, treatment of these diseases faces significant barriers in terms of both development and testing. These include the identification and selection of appropriate patient populations for therapeutic trials, and the consideration of multimodal data from brain imaging and "omics" technologies (Editor's note: genomics, transcriptomics, etc.), whose analysis still remains complex.

The latter being able to provide biomarkers for progression and to assist in isolating risk factors, one of the objectives of this new IPL will be to demonstrate the potential of this data in the identification of early alterations, or, and this is the name of the project, in the "design of imaging biomarkers of neurodegenerative diseases for clinical trials and study of their genetic associations".

To this end, Inria will be particularly involved in the statistical and bioinformatics components, while four ICM teams will provide their expertise in the field of neurodegenerative diseases, specifically: Alzheimer's disease, Parkinson's disease, frontotemporal dementia and multiple sclerosis.

We are facing a real medical and societal challenge: to be able to develop new treatments, it is essential to factor in this multimodal data, which is still complex today. Herein lies the full importance of this project.

Olivier Colliot, Aramis project team

Located on the Pitié-Salpêtrière university-hospital site, ICM has established itself as one of the world leaders in research into neurodegenerative diseases. Inria's partner for more than five years, this new large-scale project will strengthen this partnership.

Keywords: Maladies neurodégénératives Données multimodales IPL Inria project labs Inria Project Lab ICM